Device/Diagnostics Quarterly Deal Statistics, Q3 2012
Executive Summary
Device companies raised a total of $801 million in 2012’s third quarter, an 18% drop from Q2’s $977 million. Approximately $2.6 billion was spent on device acquisitions, exactly $2 billion less than Q2’s total. Diagnostic/research company financings totaled $484 million during Q3 2012, up from last quarter’s $336 million. And while diagnostic/research M&A activity was not as prolific as last quarter, tech transfer deals are seeing a resurgence.
You may also be interested in...
Option-To-Acquire In Medical Device Deals Rarely Gets Exercised
For a device start-up, an option to acquire presents a clear path to liquidity, but there are drawbacks. An analysis of deals in Elsevier’s Strategic Transactions suggests the importance of such options to the overall merger and acquisition ecosystem might be overblown.
Could Medtronic’s Kanghui Purchase Set Course For US Entry?
Last month Medtronic agreed to pay close to $800 million for Chinese orthopedics implant maker China Kanghui Holdings. To be sure, the purchase of Kanghui secures Medtronic’s footing in China, one of the fastest growing health care economies in the world. In addition, it likely will help Medtronic close in on its goal of bringing in 20% of its revenue from emerging markets.
Danaher Expands Diagnostics Offerings Via $338 Mil. IRIS Acquisition
Firm will combine IRIS International with its Beckman Coulter diagnostics unit. Deal adds leading worldwide provider of automated urine microscopy and chemistry systems, including IRIS’ fully-automated iQ bench-top analyzer for urine microscopy.